## Edgar Filing: VistaGen Therapeutics, Inc. - Form 4

Form 4	erapeutics, Inc.										
January 13, 20	_								PPROVAL		
FORM	4 UNITED	STATES	SECU	RITIES A	AND EX	CHANG	E COMMISSIO	T -	PPROVAL		
Check this		DIAILS		ashington				Number:	3235-0287		
if no longe	ar.	AENT O	ГСЦАТ	NCES IN	DENIEL		WNERSHIP OF	Expires:	January 31, 2005		
subject to Section 16 Form 4 or	r Chai		RITIES	WINEKSHIF OF	Estimated burden hou response	urs per					
Form 5 obligations may contin <i>See</i> Instruct 1(b).	s Section 17(	(a) of the l	Public U	Jtility Hol	ding Co		ange Act of 1934, t of 1935 or Secti 1940	on			
(Print or Type Re	esponses)										
1. Name and Address of Reporting Person <u>*</u> SAXE JON S			Symbol	er Name <b>an</b> en Therat		r Trading	5. Relationship of Reporting Person(s) to Issuer				
(Last)	(First) (	Middle)		of Earliest T		-	(Cho	eck all applicabl	e)		
(Last)	(11151) (	winduic)		Day/Year)	ransaction		Director 10% Owner				
	GEN THERAPE LLERTON AVI		01/11/2	-			Difficer (give below)	ve titleOth below)	ner (specify		
(Street)			4. If Amendment, Date Original				6. Individual or Joint/Group Filing(Check				
SOUTH SAN			Filed(Mo	onth/Day/Yea	ır)		Applicable Line) _X_ Form filed by Form filed by Person	One Reporting P More than One R			
FRANCISCO	D, CA 94080										
(City)	(State)	(Zip)	Tał	ole I - Non-l	Derivative	Securities	Acquired, Disposed	of, or Beneficia	lly Owned		
	2. Transaction Date Month/Day/Year)	Execution any	Date, if	3. Transactio Code (Instr. 8)	Disposed	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						(A) or	Transaction(s) (Instr. 3 and 4)				
				Code V	Amount	(D) Price	(Instr. 5 and 4)				
Reminder: Repo	rt on a separate line	e for each cl	ass of sec	urities bene	ficially ow	ned directly	or indirectly.				
					inforr requi	nation con red to resp ays a curre	spond to the colle tained in this forn ond unless the fo ently valid OMB co	n are not rm	SEC 1474 (9-02)		
	Tab					sposed of, or convertible	r Beneficially Owned securities)	1			
1. Title of 2.	3. Trar	saction Dat	e 3A. De	eemed	4.	5. Numb	er of 6. Date Exerc	visable and	7. Title and A		

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

## Edgar Filing: VistaGen Therapeutics, Inc. - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)					
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant for Common Stock	\$ 10	01/11/2015		А		20,000		01/11/2015	01/11/2020	Common Stock	20,000

## **Reporting Owners**

Reporting Owner Name / AddressRelationsHummed SectorsDirector10% OwnerOfficerOtherSAXE JON S<br/>C/O VISTAGEN THERAPEUTICS, INC.<br/>343 ALLERTON AVENUE<br/>SOUTH SAN FRANCISCO, CA 94080--<td

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.